Journal of Internal Medicine · 1992 · 11 citations · 12 references
MedicineCardiologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyPreventive CardiologyCardiac MedicationsCardiac PharmacotherapyCardiovascular PharmacologyDiuretic TherapyHeart FailureHeart Failure PharmacotherapyAntihypertensive Drug TherapyBlood PressureConcomitant TherapyFunctional Class AssessmentHeart Failure PharmacologyHeart RateSystolic Blood PressureTreatment Periods
The non-sulfhydryl selective angiotensin-converting enzyme inhibitor benazepril (20 mg daily) was compared with hydrochlorothiazide (50 mg daily) in post-infarction (6-24 months) patients with symptomatic (NYHA functional class 2) mild heart failure. No concomitant drug therapy was given. The study had a double-blind cross-over design with 3-month treatment periods. Both drugs were well tolerated, and both caused a similar reduction in systolic blood pressure. Heart rate was higher with the diuretic. Benazepril improved the NYHA functional class in 17 out of 29 (59%) patients, whereas one patient improved with hydrochlorothiazide (P = 0.0004). With regard to global efficacy score, benazepril was also superior. Thus, angiotensin-converting enzyme inhibitors may be superior to diuretics as first-choice therapy in symptomatic mild heart failure.
12
TREATMENT OF PATIENTS WITH SYMPTOMLESS LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION
Norman Sharpe, Heather Smith, Judy Murphy et al. · The Lancet · 1988 · 483 citations